Drug Patent Watch

MAY 17, 2024

Annual Drug Patent Expirations for TYMLOS Tymlos is a drug marketed by Radius and is included in one NDA. It is available from one supplier. There are eight patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 17, 2024

Annual Drug Patent Expirations for NEXLETOL Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are four… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 17, 2024

Annual Drug Patent Expirations for NEXLIZET Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are six… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 17, 2024

Annual Drug Patent Expirations for TADLIQ Tadliq is a drug marketed by Cmp Dev Llc and is included in one NDA. It is available from one supplier. There are two… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 17, 2024

Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. It is available from one supplier. There are fifty-eight… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 15, 2024

Annual Drug Patent Expirations for QVAR+REDIHALER Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. It is available from three suppliers. There are fifteen… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 14, 2024

Annual Drug Patent Expirations for RECARBRIO Recarbrio is a drug marketed by Msd Merck Co and is included in one NDA. It is available from one supplier. There is one… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 14, 2024

Annual Drug Patent Expirations for GAVRETO Gavreto is a drug marketed by Blueprint Medicines and is included in one NDA. It is available from one supplier. There are three patents… Source

Medicine 59

Medicine Drugs Marketing 59

Drug Patent Watch

MAY 14, 2024

Annual Drug Patent Expirations for PLUVICTO Pluvicto is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for NYMALIZE Nymalize is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are six patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are seventy patents… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for REXULTI Rexulti is a drug marketed by Otsuka and is included in one NDA. It is available from two suppliers. There are six patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for PARSABIV Parsabiv is a drug marketed by Kai Pharms Inc and is included in one NDA. It is available from one supplier. There are seven… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for DUOBRII Duobrii is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There are seven patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for BRYHALI Bryhali is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There are three patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for ERLEADA Erleada is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are ten patents… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for BALVERSA Balversa is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are six patents… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier. There are eleven patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 13, 2024

Annual Drug Patent Expirations for SCEMBLIX Scemblix is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting… Source

Drugs 59

Drugs Marketing 59

Drug Patent Watch

MAY 11, 2024

Annual Drug Patent Expirations for OMONTYS Omontys is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug. This drug… Source

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MAY 11, 2024

Annual Drug Patent Expirations for OMONTYS+PRESERVATIVE+FREE Omontys Preservative Free is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.…

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MAY 12, 2024

Annual Drug Patent Expirations for ALIQOPA Aliqopa is a drug marketed by Bayer Healthcare and is included in one NDA. It is available from one supplier. There are four patents… Source

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MAY 12, 2024

Annual Drug Patent Expirations for ONGENTYS Ongentys is a drug marketed by Neurocrine and is included in one NDA. It is available from two suppliers. There are nine patents protecting… Source

Drugs 52

Drugs Marketing 52

Drug Discovery World

MAY 14, 2024

Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. What evidence is there showing that the AI-AAM method is effective in identifying drug candidates? Secure your free place today.

Drugs 52

Drugs Marketing Research Development 52

XTalks

MAY 15, 2024

These bans reflect concerns from traditional meat industries about market competition and consumer acceptance. In the US, cultivated meat has received approval from the US Food and Drug Administration (FDA) and the US Department of Agriculture (USDA). Following suit, lab-grown meat was recently banned in Florida and Alabama.

Production 98

Production Regulation Marketing Manufacturing 98

Drug Discovery World

MAY 16, 2024

Carthera, a spin-off from Sorbonne University, has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the use of carboplatin in the treatment of malignant glioma. We are thrilled to receive orphan drug designation from the European and US authorities.

Trials 52

Trials Drugs Clinical Trials Clinical Trials 52

XTalks

MAY 17, 2024

Eli Lilly announced it has reached a settlement with a medical spa selling counterfeit versions of the company’s blockbuster tirzepatide GLP-1 drugs Mounjaro and Zepbound. Fellow GLP-1 maker over companies selling compounded versions of its semaglutide products, Ozempic and Wegovy, and using fraudulent marketing.

Sales 52

Sales FDA Approval Pharmacy Production 52

Cloudbyz

MAY 17, 2024

As AI increasingly becomes a cornerstone in clinical research and drug development, it is crucial for industry stakeholders to grasp the extensive implications of this regulation. This could challenge the swift market introduction of innovative AI solutions, potentially leading to prolonged development timelines and increased costs.

Life Science 79

Life Science Clinical Trials Clinical Trials Trials 79

Drug Discovery World

MAY 13, 2024

Using structural biology as central to vaccine design and development, and to drug discovery more generally, is what we mean by “rational design.” The pandemic brought together earlier efforts in structural vaccinology and synthetic biology (mRNA design and packing) to bring vaccines to market in record time.

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Drug Discovery World

MAY 15, 2024

Marketed anti-VEGF therapeutics effectively neutralise retinal VEGF levels and reduce both vascular leak and consequential oedema, resulting in a temporary improvement in vision, but do nothing to address the underlying pathology – capillary drop-out 5. In 2019 there were >14.2 million by 2029, according to GlobalData.

Development 64

Development Gene Therapy Compliance Production 64